Novartis’ CML drug hits PhIII targets
Asciminib was superior to bosutinib in inducing a major molecular response
Read More
Tag: Ph+ CML-CP
Tasigna cleared for use in children with rare leukemia
The US Food and Drug Administration is allowing use of Novartis’ Tasigna to treat paediatric patients with a rare form of leukaemia.
Read More
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
